Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02971748 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
A Phase 2 study of Anatomic Stage IIIB Breast Cancer AJCC v8 and Anatomic Stage IIIC Breast Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT02971748 is a Phase 2 study of Anatomic Stage IIIB Breast Cancer AJCC v8 and Anatomic Stage IIIC Breast Cancer AJCC v8 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants, below the 324-participant average among 33 other Anatomic Stage IIIB Breast Cancer AJCC v8 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02971748, a Phase 2 study of Anatomic Stage IIIB Breast Cancer AJCC v8 and Anatomic Stage IIIC Breast Cancer AJCC v8, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well pembrolizumab works in treating patients with hormone receptor positive inflammatory breast cancer that has not spread to other parts of the body, who are receiving hormone therapy and did not achieve a pathological complete response to chemotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-01-26 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02971748
The ClinicalTrials.gov registry entry for NCT02971748 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 33 other Anatomic Stage IIIB Breast Cancer AJCC v8 trials with a reported enrollment target (89% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Anatomic Stage IIIB Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02971748 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02971748 about?
NCT02971748 is a clinical study titled "Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy". This phase II trial studies how well pembrolizumab works in treating patients with hormone receptor positive inflammatory breast cancer that has not spread to other parts of the body, who are receiving hormone therapy and did not achieve a pathological complete response to chemotherapy. Immunotherap...
What is the current status of trial NCT02971748?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-01-26. Estimated completion is 2027-12-31.
What conditions does trial NCT02971748 study?
This clinical trial studies the following conditions: Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8.
What interventions are being tested in trial NCT02971748?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02971748?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02971748 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anatomic Stage IIIB Breast Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
RECRUITING · Phase 2
-
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
COMPLETED · Phase 2
-
A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment
RECRUITING · NA
Explore more on PlainTrial
Anatomic Stage IIIB Breast Cancer AJCC v8
All registered trials for this condition
Anatomic Stage IIIC Breast Cancer AJCC v8
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.